Previous close | 66.81 |
Open | 66.73 |
Bid | 66.44 x 3200 |
Ask | 66.70 x 800 |
Day's range | 66.51 - 67.16 |
52-week range | 53.63 - 71.70 |
Volume | |
Avg. volume | 7,299,901 |
Market cap | 206.699B |
Beta (5Y monthly) | 0.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.44 (2.15%) |
Ex-dividend date | 24 Feb 2022 |
1y target est | N/A |
WILMINGTON, Del., May 23, 2022--AstraZeneca advances its ambition to redefine cancer care with new data to be presented across its diverse and industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022.
WILMINGTON, Del., May 15, 2022--Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, an inhaled corticosteroid (ICS), used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma.1,2
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced that the presentations from the May 10th and 11th Depositary Receipts Virtual Investor Conference (“dbVIC”) are now available for on-demand viewing. The event featured presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in China, Hong Kong, Germany, Portugal, South Africa, Spain and the UK presented their equity stories and